Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:ENTX NASDAQ:IRD OTCMKTS:LTUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.23-2.4%$1.41$0.86▼$3.36$74.50M0.14315,479 shs120,794 shsENTXEntera Bio$1.82-0.5%$1.94$1.50▼$2.79$83.11M1.69100,381 shs32,761 shsIRDOpus Genetics$1.40+2.2%$1.18$0.65▼$1.75$83.87M0.07513,609 shs214,294 shsLTUSLotus Pharmaceuticals$0.01-18.8%$0.01$0.00▼$0.01$17.19M-2.3451,162 shs1,032 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-4.55%-10.64%-11.27%+3.28%-51.54%ENTXEntera Bio+1.67%-8.50%-8.50%-10.99%-8.04%IRDOpus Genetics-0.72%-2.14%+14.17%+48.33%+136,999,900.00%LTUSLotus Pharmaceuticals0.00%-24.42%-19.05%-9.72%+71.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.23-2.4%$1.41$0.86▼$3.36$74.50M0.14315,479 shs120,794 shsENTXEntera Bio$1.82-0.5%$1.94$1.50▼$2.79$83.11M1.69100,381 shs32,761 shsIRDOpus Genetics$1.40+2.2%$1.18$0.65▼$1.75$83.87M0.07513,609 shs214,294 shsLTUSLotus Pharmaceuticals$0.01-18.8%$0.01$0.00▼$0.01$17.19M-2.3451,162 shs1,032 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals-4.55%-10.64%-11.27%+3.28%-51.54%ENTXEntera Bio+1.67%-8.50%-8.50%-10.99%-8.04%IRDOpus Genetics-0.72%-2.14%+14.17%+48.33%+136,999,900.00%LTUSLotus Pharmaceuticals0.00%-24.42%-19.05%-9.72%+71.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.00Buy$7.00469.11% UpsideENTXEntera Bio 4.00Strong Buy$10.00449.45% UpsideIRDOpus Genetics 3.00Buy$7.33423.81% UpsideLTUSLotus Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LTUS, ENTX, IRD, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025ABOSAcumen PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.008/11/2025ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/27/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/17/2025ABOSAcumen PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$3.03 per shareN/AENTXEntera Bio$166K500.64N/AN/A$0.23 per share7.91IRDOpus Genetics$10.99M7.63N/AN/A$0.21 per share6.67LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$102.33M-$2.28N/AN/AN/AN/A-81.39%-61.96%11/11/2025 (Estimated)ENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)IRDOpus Genetics-$57.53M-$1.92N/AN/AN/A-377.89%-384.33%-148.90%11/11/2025 (Estimated)LTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/ALatest LTUS, ENTX, IRD, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025IRDOpus Genetics-$0.25-$0.12+$0.13-$0.12$4.27 million$2.88 million8/12/2025Q2 2025ABOSAcumen Pharmaceuticals-$0.54-$0.68-$0.14-$0.68N/AN/A8/8/2025Q2 2025ENTXEntera Bio-$0.11-$0.06+$0.05-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.265.975.97ENTXEntera BioN/A10.4710.47IRDOpus Genetics0.061.901.90LTUSLotus PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%ENTXEntera Bio14.11%IRDOpus Genetics14.97%LTUSLotus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals7.10%ENTXEntera Bio10.38%IRDOpus Genetics6.60%LTUSLotus PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million56.27 millionOptionableENTXEntera Bio2045.66 million40.92 millionOptionableIRDOpus Genetics1459.91 million55.95 millionN/ALTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableLTUS, ENTX, IRD, and ABOS HeadlinesRecent News About These CompaniesPhase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett SyndromeSeptember 15 at 5:45 PM | appliedclinicaltrialsonline.comAAcadia Pharmaceuticals publishes interim LOTUS study data in journalSeptember 12, 2025 | msn.comReal World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental ...September 12, 2025 | finance.yahoo.comPTT to sell stake in Taiwan pharmaceuticals firmJuly 25, 2025 | msn.comSamarsh Capital, Vyom Partners, Blue Lotus Lead INR 50 Cr Investment in Sai ParenteralsJuly 8, 2025 | msn.comGeely’s Lotus says ‘no plans’ to close any factoryJuly 2, 2025 | msn.comLotus Pharmaceutical Co Ltd (1795) - Investing.com UKJune 26, 2025 | uk.investing.comLotus Therapeutics Appoints Leslie Felix as Chief Growth OfficerJune 4, 2025 | finance.yahoo.comSperanza Therapeutics Launches New Division to Help Pharma Manufacturers Adapt to Market ShiftsApril 23, 2025 | finance.yahoo.comLotus Pharmaceutical becomes strategic partner for…February 5, 2025 | pharmiweb.comPTaiwan’s pharma firm Lotus acquires edema medicine rights in Vietnam from SanofiJanuary 9, 2025 | theinvestor.vnTlotus exchangeDecember 28, 2024 | everythingexperiential.businessworld.inEBoryung, Lotus Pharma signs CDMO deal on anticancer injectionDecember 12, 2024 | kedglobal.comKLotus Pharmaceuticals Inc Price / BookNovember 20, 2024 | investing.comLotus Bakeries: When Growth Potential Meets Pricey ExpectationsNovember 13, 2024 | seekingalpha.comUSA Knotless Surgical Sutures Market Expected to Reach USD 258.7 Million by 2033 at a 3.6% of CAGRNovember 1, 2024 | fmiblog.comF20 Shows Like ‘Black Mirror’ That’ll Definitely Mess with Your HeadNovember 1, 2024 | yahoo.comLotus Bakeries: A Sweet Business With Exponential GrowthOctober 27, 2024 | seekingalpha.comA Forbidden Lotus Elise Rival Is for Sale in the U.S. Right NowOctober 24, 2024 | msn.comNatasha Rothwell Opens Up About 'The White Lotus' Season 3, 'How to Die Alone' & MoreOctober 23, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTUS, ENTX, IRD, and ABOS Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.23 -0.03 (-2.38%) Closing price 04:00 PM EasternExtended Trading$1.22 -0.01 (-0.81%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Entera Bio NASDAQ:ENTX$1.82 -0.01 (-0.55%) Closing price 04:00 PM EasternExtended Trading$1.82 0.00 (0.00%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Opus Genetics NASDAQ:IRD$1.40 +0.03 (+2.19%) Closing price 04:00 PM EasternExtended Trading$1.39 -0.01 (-0.71%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0065 0.00 (-18.75%) As of 11:39 AM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
